The DOI matches its Crossref record.
Early eradication therapy against Pseudomonas aeruginosa in cystic fibrosis patients
Open accessAbstract
In cystic fibrosis (CF) patients early antibiotic treatment of lung infection has been shown to lead to Pseudomonas aeruginosa eradication. The present study determined: 1) the time period from eradication to new P. aeruginosa acquisition; 2)P. aeruginosa re-growth and new acquisition; and 3) the impact of eradication therapy on lung function, antimicrobial resistance, emergence of other pathogens and treatment costs. Ciprofloxacin and colistin were used to eradicate P. aeruginosa in 47 CF patients. Bacterial pathogens, lung function decline,P. aeruginosa antimicrobial resistance and anti-pseudomonal serum antibodies were assessed quarterly and compared with an age-matched CF control group. Additionally, costs of antibiotic therapy in both groups were assessed. Early antibiotic therapy leads to a P. aeruginosa free-period of a median (range) of 18 (4–80) months. New acquisition with different P. aeruginosa genotypes occurs in 73% of episodes. It also delays the decline of lung function compared with chronically infected patients, prevents the occurrence of antibiotic resistant P. aeruginosa strains, does not lead to emergence of other pathogens, and significantly reduces treatment costs. The treatment substantially lowers P. aeruginosa prevalence in CF. In conclusion, early antibiotic therapy exerts beneficial effects on the patient's clinical status and is cost-effective compared with conventional antibiotic therapy for chronically infected cystic fibrosis patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
O'Sullivan, B. P., & Freedman, S. D. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60327-5 · Cited by 1,320
Primary ciliary dyskinesia: a consensus statement on diagnostic and treatment approaches in children
Barbato, A., Frischer, T., Kuehni, C. E., Snijders, D., Azevedo, I., Baktai, G., Bartoloni, L., Eber, E., Escribano, A., Haarman, E., et al. (2009) · European Respiratory Journal · doi:10.1183/09031936.00176608 · Cited by 528
Martínez-García, M. A., Soler-Cataluña, J.-J., Perpiñá-Tordera, M., Román-Sánchez, P., & Soriano, J. (2007) · Chest · doi:10.1378/chest.07-0490 · Cited by 483
Treatment of lung infection in patients with cystic fibrosis: Current and future strategies
Döring, G., Flume, P., Heijerman, H., & Elborn, J. S. (2012) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2012.10.004 · Cited by 474
Self-citationMortality in bronchiectasis: a long-term study assessing the factors influencing survival
Loebinger, M. R., Wells, A. U., Hansell, D. M., Chinyanganya, N., Devaraj, A., Meister, M., & Wilson, R. (2009) · European Respiratory Journal · doi:10.1183/09031936.00003709 · Cited by 414
Metadata
- Authors
- Taccetti, G., Campana, S., Festini, F., Mascherini, M., & Döring, G.
- Venue
- European Respiratory Journal
- Publisher
- European Respiratory Society (ERS)
- Published
- 2005-09
- Volume
- 26
- Issue
- 3
- Pages
- 458-461
- ISSN
- 0903-1936 (ISSN-L)
- 1399-3003
- OpenAlex
- W2131539997
- Cited by
- 181
- References
- 0
- FWCI
- 9.37
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Early eradication therapy against Pseudomonas aeruginosa in cystic fibrosis patients. https://app.cochat.ai/papers/10.1183/09031936.05.00009605
- The paper
- Taccetti, G., Campana, S., Festini, F., Mascherini, M., & Döring, G. (2005). Early eradication therapy against Pseudomonas aeruginosa in cystic fibrosis patients. European Respiratory Journal. https://doi.org/10.1183/09031936.05.00009605
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.